All In Biotech

Drug Trial Radar · NCT04195750

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 755 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

755

Actual

Start

Feb 27, 2020

Primary completion

Apr 15, 2024

Study completion Oct 14, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Dec 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS.

Conditions

  • Carcinoma, Renal Cell

Interventions

  • BelzutifanDrug

    Oral tablets

  • EverolimusDrug

    Oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 39 months
  2. Overall Survival (OS)Time frame: Up to approximately 49 months

Locations

172 sites in 23 countries. Site status is shown where the registry gives one.

  • Faculty Office Towers 1132 ( Site 1538)

    Birmingham, Alabama

  • University of California San Diego Moores Cancer Center ( Site 1546)

    La Jolla, California

  • St. Joseph Heritage Healthcare Local Lab ( Site 1531)

    Santa Rosa, California

  • University of Colorado Cancer Center ( Site 1540)

    Aurora, Colorado

  • UCHealth Highlands Ranch Hospital ( Site 1560)

    Highlands Ranch, Colorado

  • Sibley Memorial Hospital ( Site 1559)

    Washington D.C., District of Columbia

  • Northwest Georgia Oncology Centers PC ( Site 1520)

    Marietta, Georgia

  • The University of Chicago Medical Center ( Site 1539)

    Chicago, Illinois

  • Ochsner Medical Center ( Site 1522)

    New Orleans, Louisiana

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1514)

    Baltimore, Maryland

  • Massachusetts General Hospital ( Site 1558)

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center ( Site 1501)

    Boston, Massachusetts

  • Dana Farber Cancer Institute ( Site 1505)

    Boston, Massachusetts

  • Henry Ford Cancer Center ( Site 1511)

    Detroit, Michigan

  • Hattiesburg Clinic ( Site 1509)

    Hattiesburg, Mississippi

  • St. Vincent Frontier Cancer Center ( Site 1549)

    Billings, Montana

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 1513)

    Hackensack, New Jersey

  • University of Rochester Medical Center ( Site 1543)

    Rochester, New York

  • University of North Carolina at Chapel Hill ( Site 1537)

    Chapel Hill, North Carolina

  • Oncology Hematology Care, Inc. ( Site 1524)

    Cincinnati, Ohio

  • Cleveland Clinic Main ( Site 1504)

    Cleveland, Ohio

  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1523)

    Tulsa, Oklahoma

  • Oregon Health & Science University ( Site 1553)

    Portland, Oregon

  • Abramson Cancer Center ( Site 1525)

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center ( Site 1506)

    Philadelphia, Pennsylvania

  • Medical University of South Carolina ( Site 1518)

    Charleston, South Carolina

  • Henry Joyce Cancer Clinic ( Site 1544)

    Nashville, Tennessee

  • Texas Oncology-Austin Central ( Site 1533)

    Austin, Texas

  • Texas Oncology, P.A.-Dallas ( Site 1534)

    Dallas, Texas

  • Centro Avançado de Tratamento Oncológico- CENANTRON ( Site 1657)

    Belo Horizonte, Minas Gerais, Brazil

  • Instituto de Cancer e Transplante de Curitiba ICTR ( Site 1650)

    Curitiba, Paraná, Brazil

  • Liga Norte Riograndense Contra o Cancer ( Site 1651)

    Natal, Rio Grande do Norte, Brazil

  • Hospital de Clinicas de Porto Alegre ( Site 1655)

    Porto Alegre, Rio Grande do Sul, Brazil

  • BP - A Beneficencia Portuguesa de São Paulo ( Site 1653)

    São Paulo, São Paulo, Brazil

  • BC Cancer - Vancouver Center ( Site 0155)

    Vancouver, British Columbia, Canada

  • Nova Scotia Health Authority QEII-HSC ( Site 0150)

    Halifax, Nova Scotia, Canada

  • Juravinski Cancer Centre ( Site 0154)

    Hamilton, Ontario, Canada

  • Sunnybrook Research Institute ( Site 0153)

    Toronto, Ontario, Canada

  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0151)

    Montreal, Quebec, Canada

  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0152)

    Québec, Quebec, Canada

Showing 40 of 172 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.